A Randomized, Open Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination With Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009299/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This is a randomized (1:1), open-label, multicenter, active-controlled study in patients with
previously treated CD23+ and CD20+ relapsed CLL. Patients will receive treatment with either
lumiliximab in combination with FCR or FCR alone.
提供机构：
Vivli
创建时间：
2023-09-27
